<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://pharmacopedia.wiki/index.php?action=history&amp;feed=atom&amp;title=Loratadine</id>
	<title>Loratadine - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://pharmacopedia.wiki/index.php?action=history&amp;feed=atom&amp;title=Loratadine"/>
	<link rel="alternate" type="text/html" href="https://pharmacopedia.wiki/index.php?title=Loratadine&amp;action=history"/>
	<updated>2026-05-28T18:33:48Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.46.0-beta</generator>
	<entry>
		<id>https://pharmacopedia.wiki/index.php?title=Loratadine&amp;diff=6795&amp;oldid=prev</id>
		<title>MDElliottMD: home-claude category backfill (parser-claude gap closure)</title>
		<link rel="alternate" type="text/html" href="https://pharmacopedia.wiki/index.php?title=Loratadine&amp;diff=6795&amp;oldid=prev"/>
		<updated>2026-05-23T10:43:32Z</updated>

		<summary type="html">&lt;p&gt;home-claude category backfill (parser-claude gap closure)&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw-interface=&quot;&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 10:43, 23 May 2026&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l21&quot;&gt;Line 21:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 21:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;references /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;references /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[[Category:H1 receptor antagonists]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[[Category:Antihistamines]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;!-- diff cache key mediawiki:diff:1.41:old-5921:rev-6795:php=table --&gt;
&lt;/table&gt;</summary>
		<author><name>MDElliottMD</name></author>
	</entry>
	<entry>
		<id>https://pharmacopedia.wiki/index.php?title=Loratadine&amp;diff=5921&amp;oldid=prev</id>
		<title>MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #105</title>
		<link rel="alternate" type="text/html" href="https://pharmacopedia.wiki/index.php?title=Loratadine&amp;diff=5921&amp;oldid=prev"/>
		<updated>2026-05-23T03:46:15Z</updated>

		<summary type="html">&lt;p&gt;parser-claude batch MedTemplate pre-fill, Top 300 #105&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;{{MedTemplate&lt;br /&gt;
| generic           = Loratadine&lt;br /&gt;
| brand             = Claritin, Alavert, Tavist ND&lt;br /&gt;
| structure         =&lt;br /&gt;
| classes           = [[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist (second-generation)]], [[:Category:Antihistamines|Antihistamine]]&lt;br /&gt;
| uses              = &amp;lt;vote slug=&amp;quot;allergic-rhinitis-use&amp;quot;&amp;gt;Allergic rhinitis&amp;lt;/vote&amp;gt;, &amp;lt;vote slug=&amp;quot;chronic-urticaria-use&amp;quot;&amp;gt;Chronic idiopathic urticaria&amp;lt;/vote&amp;gt;&lt;br /&gt;
| starting_dose     = 10 mg PO once daily&lt;br /&gt;
| preparations      = 10 mg tablets; 5 mg ODT and chewables; 1 mg/mL oral syrup; combo Claritin-D (with pseudoephedrine, behind-counter)&lt;br /&gt;
| fda_max           = 10 mg/d (adults)&lt;br /&gt;
| pill_id           =&lt;br /&gt;
| routes            = Oral&lt;br /&gt;
| onset             = 1-3 hours (slower onset than cetirizine; symptom relief somewhat less)&lt;br /&gt;
| duration          = 24 hours&lt;br /&gt;
| halflife          = ~8 hours (parent); ~28 hours (desloratadine, the active metabolite, marketed separately as Clarinex)&amp;lt;ref name=&amp;quot;claritin-label&amp;quot;&amp;gt;FDA Prescribing Information, Claritin (loratadine), Bayer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019835s050lbl.pdf&amp;lt;/ref&amp;gt;&lt;br /&gt;
| bioavailability   = High (oral; food prolongs absorption modestly)&amp;lt;ref name=&amp;quot;claritin-label&amp;quot; /&amp;gt;&lt;br /&gt;
| pregnancy         = Generally considered safe; widely used. Loratadine and cetirizine are the most-recommended 2nd-gen H1s in pregnancy and lactation.{{citation needed}}&lt;br /&gt;
| legal             = OTC in US&lt;br /&gt;
| mechanism         = &amp;lt;vote slug=&amp;quot;loratadine-mech-claim&amp;quot;&amp;gt;Loratadine is a selective peripheral H1 receptor antagonist with very limited blood-brain barrier penetration, producing antihistaminic effect without significant sedation; it is metabolized by CYP3A4 and CYP2D6 to desloratadine, the longer-half-life active metabolite.&amp;lt;/vote&amp;gt; Less reliably anticholinergic than first-generation H1s; minimal antiemetic effect. Desloratadine (Clarinex) is the active enantiomer-of-metabolite version marketed as a Rx alternative.&lt;br /&gt;
}}&lt;br /&gt;
&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>MDElliottMD</name></author>
	</entry>
</feed>